Here are four observations:
1. Epclusa is a fixed-dose combination tablet.
2. The drug is approved for use in combination with ribavirin for patients with moderate to severe cirrhosis.
3. Epclusa’s most common side effects are headache and fatigue.
4. Gilead Sciences has courted controversy in the past. The company’s Sovaldi and Harvoni drugs, also intended for HCV treatment, were criticized for their high prices.
More articles on GI/endoscopy:
4 key trends in the $2.35B GI/endoscopic devices market
Merit Health Natchez adds Dr. W. Kirk Mullins: 4 points
5 most read GI/endoscopy stories: June 20 — June 24
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.